We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UTI:NYSEUniversal Technical Institute Inc Analysis

Data as of 2026-05-08 - not real-time

$35.49

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Universal Technical Institute is trading in a bullish market environment with the 20‑day SMA above the 50‑day SMA and price firmly above the 200‑day SMA, yet the MACD has turned bearish and the RSI sits near the mid‑range, suggesting mixed short‑term momentum. Revenue is growing at roughly 10% annually and margins remain solid (gross margin above 55%, operating margin around 7%), supporting a strong earnings narrative. The stock carries a high valuation – PE close to 37× and a price‑to‑book near 6× – and a discounted cash‑flow model values the company well below the current market price, indicating potential overvaluation. Recent positive catalysts include a strategic three‑year partnership with Fuji Spray Auto and an earnings beat in Q1 2026, which have helped sustain analyst confidence (strong‑buy consensus) and an upside target of around $40‑41. However, volatility is elevated (over 40% 30‑day) and leverage is notable, with debt-to‑equity approaching 86%, adding downside risk if earnings falter.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram and price near recent support
  • Increasing volume indicating potential accumulation
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth and solid margin profile
  • Strategic partnership with Fuji Spray Auto expanding program offerings
  • Analyst target price suggesting ~15% upside

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Sustainable ROE around 17% and stable cash flow generation
  • Elevated leverage and lack of dividend limiting total return
  • Sector stability within consumer defensive education services

Key Metrics & Analysis

Financial Health

Revenue Growth9.60%
Profit Margin6.28%
P/E Ratio37.0
ROE17.44%
ROA5.65%
Debt/Equity86.20
P/B Ratio5.8
Op. Cash Flow$77.5M
Free Cash Flow$41.1M

Technical Analysis

TrendBullish
RSI45.8
Support$31.51
Resistance$38.98
MA 20$36.62
MA 50$36.47
MA 200$30.45
MACDBearish
VolumeIncreasing
Fear & Greed Index90.93

Valuation

Fair Value$12.76
Target Price$41.50
Upside/Downside16.93%
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.82
Volatility41.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.